For which types of research is the anti-RIgG(Fc)Fab-N-MMAF ADC most effective?

The anti-RIgG(Fc)Fab-N-MMAF ADC is particularly effective in research focused on evaluating ADC therapies, including toxicity studies and screening of rabbit monoclonal antibodies for potential as ADC candidates. It serves as an efficient and economical tool in preclinical ADC development.

How can the efficacy of the anti-RIgG(Fc)Fab-N-MMAF ADC be quantitatively assessed in laboratory settings?

The efficacy of the anti-RIgG(Fc)Fab-N-MMAF ADC can be assessed through quantitative assays such as cell viability tests, apoptosis assays, and binding affinity measurements. These tests help determine the ADC's ability to specifically target and kill cancer cells expressing the appropriate antigen.

How can researchers minimize non-specific binding when using the anti-RIgG(Fc)Fab-N-MMAF ADC in vitro?

To minimize non-specific binding in experiments using the anti-RIgG(Fc)Fab-N-MMAF ADC, researchers should include appropriate blocking agents and carefully titrate the ADC to find the optimal concentration. Conducting preliminary binding specificity tests can also help refine experimental conditions.

What methodologies are recommended for tracking the internalization of the anti-RIgG(Fc)Fab-N-MMAF ADC in live cell assays?

For tracking the internalization of the anti-RIgG(Fc)Fab-N-MMAF ADC in live cell assays, fluorescence microscopy or confocal imaging techniques are recommended. These methods allow for real-time visualization of the ADC as it binds to and is internalized by target cells, providing valuable insights into its mechanism of action.

What are the best practices for quantifying the cytotoxic effects of the anti-RIgG(Fc)Fab-N-MMAF ADC in tissue culture?

To quantify the cytotoxic effects of the anti-RIgG(Fc)Fab-N-MMAF ADC in tissue culture, employing assays such as MTT, XTT, or annexin V apoptosis assays is recommended. These assays provide quantitative data on cell viability and apoptosis, allowing for accurate assessment of the ADC's efficacy in inducing cell death.

Home
Products
Anti-Ab ADCs
IgG Fc
anti-RIgG(Fc)Fab-N-MMAF ADC

anti-RIgG(Fc)Fab-N-MMAF ADC (CAT#: ADC-AA-033)

This ADC product is comprised of a Fab fragment of an anti-rabbit IgG Fc specific polyclonal antibody conjugated via a noncleavable linker to MMAF. The antibody portion is a Fab fragment of a secondary antibody and the drug portion, MMAF, is a cytotoxic small molecule which binds to tubulins, interrupts microtubule dynamics, and induces cell death. This product displays no obvious toxicity without a primary antibody and can be a quite efficient and economical alternative to pre-screening rabbit monoclonal antibodies as ADC candidates.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Name
IgG Fc

Overview
The fragment crystallizable region (Fc region) is composed of the constant region of the two heavy chains that form the IgG molecule. The Fc region of IgG bears a highly conserved N-glycosylation site. Glycosylation of the Fc fragment is essential for Fc receptor-mediated activity. Fc binds to various cell receptors and complement proteins thus mediating different physiological effects of antibodies, such as opsonization, antibody dependent cellular cytotoxicity (ADCC), degranulation of mast cells, basophils, eosinophils and other processes.

Overview
Fab fragment of anti-rabbit IgG Fc specific polyclonal antibody

Species Reactivity
Rabbit

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.

Name
MMAF (Monomethyl auristatin F)

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-033. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The anti-RIgG(Fc)Fab-N-MMAF ADC has been critical in our rabbit monoclonal antibody development, offering targeted cytotoxicity without the usual toxicity.

Excellent

Using the anti-RIgG(Fc)Fab-N-MMAF ADC has streamlined our pre-screening process, providing reliable results with its stable MMAF linkage.

Excellent

Creative Biolabs' anti-RIgG(Fc)Fab-N-MMAF ADC shows impressive specificity and effectiveness in disrupting microtubule dynamics, enhancing our cytotoxic assays.

Excellent

The noncleavable linker in the anti-RIgG(Fc)Fab-N-MMAF ADC ensures consistent delivery of the cytotoxin, greatly improving our experimental outcomes.

Excellent

Our lab values the anti-RIgG(Fc)Fab-N-MMAF ADC for its precise action and minimal toxicity, crucial for developing safe therapeutic antibodies.

Q: 1: For which types of research is the anti-RIgG(Fc)Fab-N-MMAF ADC most effective?
A: The anti-RIgG(Fc)Fab-N-MMAF ADC is particularly effective in research focused on evaluating ADC therapies, including toxicity studies and screening of rabbit monoclonal antibodies for potential as ADC candidates. It serves as an efficient and economical tool in preclinical ADC development.
Q: 2: How can the efficacy of the anti-RIgG(Fc)Fab-N-MMAF ADC be quantitatively assessed in laboratory settings?
A: The efficacy of the anti-RIgG(Fc)Fab-N-MMAF ADC can be assessed through quantitative assays such as cell viability tests, apoptosis assays, and binding affinity measurements. These tests help determine the ADC's ability to specifically target and kill cancer cells expressing the appropriate antigen.
Q: 3: How can researchers minimize non-specific binding when using the anti-RIgG(Fc)Fab-N-MMAF ADC in vitro?
A: To minimize non-specific binding in experiments using the anti-RIgG(Fc)Fab-N-MMAF ADC, researchers should include appropriate blocking agents and carefully titrate the ADC to find the optimal concentration. Conducting preliminary binding specificity tests can also help refine experimental conditions.
Q: 4: What methodologies are recommended for tracking the internalization of the anti-RIgG(Fc)Fab-N-MMAF ADC in live cell assays?
A: For tracking the internalization of the anti-RIgG(Fc)Fab-N-MMAF ADC in live cell assays, fluorescence microscopy or confocal imaging techniques are recommended. These methods allow for real-time visualization of the ADC as it binds to and is internalized by target cells, providing valuable insights into its mechanism of action.
Q: 5: What are the best practices for quantifying the cytotoxic effects of the anti-RIgG(Fc)Fab-N-MMAF ADC in tissue culture?
A: To quantify the cytotoxic effects of the anti-RIgG(Fc)Fab-N-MMAF ADC in tissue culture, employing assays such as MTT, XTT, or annexin V apoptosis assays is recommended. These assays provide quantitative data on cell viability and apoptosis, allowing for accurate assessment of the ADC's efficacy in inducing cell death.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-052	Protein A-VC-MMAE ADC	VC (valine-citrulline)	MMAE (Monomethyl auristatin E)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-021	anti-MIgG(Fc)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)
ADC-AA-049	Protein G-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-045	anti-Rat IgG(HL)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-046	anti-Rat IgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-031	anti-MIgG(Fc)Fab-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)

CAT#	Product Name	Linker	Payload
ADC-AA-020	anti-MIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)
ADC-W-537	Anti-TPBG-Mc-MMAF ADC	Mc (maleimidocaproyl)	MMAF (Monomethyl auristatin F)
ADC-AA-053	Protein A-MMAF ADC		MMAF (Monomethyl auristatin F)
ADC-W-604	Anti-FUT3-Mc-VC-PABC-MMAF ADC-3	MC-VC-PABC (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl)	MMAF (Monomethyl auristatin F)
ADC-AA-002	anti-HIgG(Fc)-C-MMAF ADC	Cleavable linkers	MMAF (Monomethyl auristatin F)

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.